Physician profile
Robert Friedman
NPI 1457337446
$18,290.39
in general payments reported to CMS, 2019-2025
46 companies · $597 in 2025
The $597 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $591 · 2021: $3,370 · 2022: $630 · 2023: $514 · 2024: $12K · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,800 · Food and Beverage: $2,449 · Travel and Lodging: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,800.00 |
| Food and Beverage | $2,449.06 |
| Travel and Lodging | $1,574.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Piramal Critical Care | $13,966.26 | 2019-2025 | |
| Abbvie INC. | $431.05 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $421.07 | 2023-2025 | Dysport |
| Allergan, INC. | $380.87 | 2019-2022 | |
| Genzyme Corporation | $280.17 | 2019-2025 | |
| Sarepta Therapeutics, INC. | $257.48 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $211.60 | 2019-2021 | |
| Vertos Medical, INC. | $161.89 | 2022 | |
| Itf Therapeutics LLC | $149.52 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $144.24 | 2019-2024 | Amvuttra |
| Supernus Pharmaceuticals, INC. | $138.29 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $129.46 | 2022-2025 | Keveyis |
| Ptc Therapeutics, INC. | $106.13 | 2019-2024 | Emflaza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.17 | 2023-2025 | Relistor |
| Tanabe Pharma America, INC. | $104.37 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.